Zymeworks Inc
NYSE:ZYME
Zymeworks Inc
NYSE:ZYME
Price:
8.26 USD
1.85%
Updated:
Apr 29, 2024
Zymeworks Inc
Cash from Operating Activities
|
Zymeworks Inc
Cash from Operating Activities Peer Comparison
Comparables:
RPTX
FUSN
AUPH
EDT
SBFM
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Zymeworks Inc
NYSE:ZYME
|
Cash from Operating Activities
-$118.3m
|
CAGR 3-Years
8%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Repare Therapeutics Inc
NASDAQ:RPTX
|
Cash from Operating Activities
-$127.2m
|
CAGR 3-Years
-176%
|
CAGR 5-Years
-59%
|
CAGR 10-Years
N/A
|
|
|
Fusion Pharmaceuticals Inc
NASDAQ:FUSN
|
Cash from Operating Activities
-$81.8m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-53%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Cash from Operating Activities
-$33.5m
|
CAGR 3-Years
22%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-22%
|
|
|
Spectral Medical Inc
TSX:EDT
|
Cash from Operating Activities
-CA$10.7m
|
CAGR 3-Years
-222%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
-2%
|
|
|
Sunshine Biopharma Inc
OTC:SBFM
|
Cash from Operating Activities
-$8.8m
|
CAGR 3-Years
-137%
|
CAGR 5-Years
-77%
|
CAGR 10-Years
-32%
|
See Also
What is Zymeworks Inc's Cash from Operating Activities?
Cash from Operating Activities
-118.3m
USD
-118.3m
USD
Based on the financial report for Dec 31, 2023, Zymeworks Inc's Cash from Operating Activities amounts to -118.3m USD.
What is Zymeworks Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
8%
8%
The average annual Cash from Operating Activities growth rates for Zymeworks Inc have been 8% over the past three years .
You don't have any saved screeners yet
